HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Eyes Using Zantac 360 Most-Recommended Ad Claim With Disclaimer Highlighting Ingredient

Executive Summary

Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.

You may also be interested in...



In Second Review Of CeraVe ‘#1 Recommended’ Claim, L’Oreal’s Survey ‘Substantially More Reliable’

With new evidence providing “reasonable basis” for claim support, National Advertising Division reverses course on 2021 decision on J&J challenge of L’Oreal USA’s use of  "#1 recommended by dermatologist" claims.

Sanofi Appealing Findings In Review Of Zantac 360 Doctor-Recommended Claims Challenged By J&J

French pharma disagrees with NAD finding, following review of a claims made in online and social media ads, retailers' websites and a TV commercial, that the claim “#1 doctor recommended medicine” for Zantac 360 refers to the brand and not famotidine, also used in other OTC heartburn remedies, including Pepcid.

Sanofi Overcomes Zantac Troubles To Gain Share In US

Sanofi Consumer Healthcare has been gaining share in the US OTC market since October 2020 after putting behind it long running Zantac troubles, according to business head Julie Van Ongevalle.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel